Stockscreener 앱 받기
140.37
0.39%
-0.55
시장 영업 전:
141.48
1.11
+0.79%
전일 마감가:
$140.92
열려 있는:
$140.87
하루 거래량:
2.25M
Relative Volume:
1.10
시가총액:
$266.80B
수익:
$54.66B
순이익/손실:
$13.58B
주가수익비율:
20.00
EPS:
7.0171
순현금흐름:
$16.05B
1주 성능:
+2.34%
1개월 성능:
-9.18%
6개월 성능:
-6.30%
1년 성능:
+14.78%
1일 변동 폭
$139.60
$141.15
1주일 범위
$137.37
$141.64
52주 변동 폭
$121.57
$170.46
노바티스 ADR Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
140.37 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,152.93 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
269.99 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
263.96 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
146.87 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
노바티스 ADR Stock (NVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 업그레이드 | Argus | Hold → Buy |
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2026-01-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-12-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-09-12 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-08-08 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-02-12 | 개시 | Morgan Stanley | Underweight |
| 2025-02-04 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-12-04 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-09-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-09-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-09-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-19 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-23 | 개시 | BMO Capital Markets | Market Perform |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-09-25 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-03-27 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2023-01-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-12-05 | 업그레이드 | Stifel | Hold → Buy |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-05-09 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 재개 | Citigroup | Buy |
| 2021-12-14 | 다운그레이드 | Redburn | Buy → Neutral |
| 2021-12-06 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 개시 | Bernstein | Mkt Perform |
| 2021-03-10 | 다운그레이드 | Argus | Buy → Hold |
| 2021-02-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-09-10 | 업그레이드 | UBS | Neutral → Buy |
| 2020-09-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-03-10 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-04-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-04-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-10 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 재개 | Jefferies | Buy |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2018-05-25 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 재확인 | Leerink Partners | Outperform |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 개시 | Liberum | Buy |
모두보기
노바티스 ADR 주식(NVS)의 최신 뉴스
Novartis stock stabilizes after trial setbacks as investor pushes for board shake-up - ad-hoc-news.de
Sarepta Therapeutics Inc Share PriceSRPT, RNS News, Articles, Quotes, & Charts (NASDAQ:SRPT) - Proactive financial news
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s - Zacks Investment Research
NVS Stock Quote Price and Forecast - CNN
Why Did Novartis (NYSE:NVS) Shares React to Study Results? - Kalkine Media
US markets today: Dow, S&P 500, Nasdaq futures indicate negative open, PPI data in focus; Apple, Novartis, others to watch - Upstox
HSBC upgrades Novartis stock rating to hold on pipeline clarity - Investing.com
HSBC upgrades Novartis stock rating to hold on pipeline clarity By Investing.com - Investing.com India
Novartis' Strong Innovation Supports Industry-Leading Margins - Morningstar
Dow closes sharply lower as oil surge fuels inflation fears - Proactive financial news
Dow slides as oil nears $100, US-Canada trade tensions escalate - Proactive financial news
Amgen Stock Eyes Worst Day Since 2000 on Novartis Lp(a) FailureAmgen (NASDAQ:AMGN) - benzinga.com
Novartis stock falls sharply after third late-stage trial failure in a week - ad-hoc-news.de
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial - finance.yahoo.com
Market movers: Novartis, Qualcomm, EchoStar, BioVie... - Proactive Investors
Novartis Down Over 12%, On Pace for Record Percent Decrease -- Data Talk - Moomoo
Dow Jones, S&P 500 futures indicate gap-down open while Nasdaq set for flat start; Novartis, Amgen, others to watch - Upstox
Novartis initiates phase 2 study of MRT-6160 for Sjögren’s disease - Investing.com Nigeria
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Novartis shares fall after second major trial setback in days - The Globe and Mail
Novartis shares plunge 10% as failed drug trial clouds growth outlook - Investing.com Nigeria
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Why is Novartis stock sliding today? - Investing.com
Novartis shares fall after heart drug fails late-stage trial - in.investing.com
Novartis shares fall after heart drug fails late-stage trial By Investing.com - Investing.com Canada
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Novartis stock slips as Jefferies and UBS stay neutral after Hybrozyme deal - ad-hoc-news.de
Novartis stock gains as remibrutinib data and Fabhalta growth offset cell therapy trial pause - ad-hoc-news.de
Novartis Up 5.6% After MS Pill Gains $3 Billion Sales Potential - ts2.tech
Novartis stock gains as remibrutinib MS data offsets CAR T trial pause - AD HOC NEWS
Why Is Novartis Stock Soaring Tuesday?Novartis (NYSE:NVS) - Benzinga
Novartis remibrutinib cuts MS relapse rates in Phase 3 - grafa.com
US markets today: Dow, S&P 500, Nasdaq futures indicate gap-down open; Novartis, Duolingo, energy stocks to watch - Upstox
Novartis shares rise after multiple sclerosis drug hits late-stage trial goals - Investing.com Australia
Novartis stock steadies after pause of autoimmune cell therapy trials - AD HOC NEWS
Novartis stock trades mixed as investors weigh post-earnings outlook - ad-hoc-news.de
Novartis stock trades below consensus target as post-earnings digestion continues - ad-hoc-news.de
Novartis stock holds steady as investors digest latest 2026 earnings and guidance - ad-hoc-news.de
Novartis AGADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Novartis stock holds steady as oncology and Alzheimer’s pipeline draws attention - ad-hoc-news.de
Novartis stock edges lower as investors look past recent FDA win - ad-hoc-news.de
India Central Nervous System Therapeutic Market Outlook, 2033 - grandviewresearch.com
Novartis stock holds firm after Q2 2026 growth and dual listing support - ad-hoc-news.de
Alibaba Group ADR shares decline over 4% during pre-market hours; focus on AI plans after $10 billion new issue - Upstox
Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors - ChartMill
Novartis stock extends its rally as investors weigh valuation and cardiovascular data plans - Ad-hoc-news.de
Novartis stock holds above $150 after orphan drug update - Ad-hoc-news.de
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - Sahm
Novartis stock holds above $150 as orphan drug milestone and earnings strength support valuation - Ad-hoc-news.de
노바티스 ADR (NVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.04%
1.55%
자본화:
|
볼륨(24시간):